Sara Nochur
Directeur/Bestuurslid bij MARINUS PHARMACEUTICALS, INC.
Vermogen: 9 017 $ op 30-04-2024
Actieve functies van Sara Nochur
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-01-2021 | - |
| Algemeen Adviseur | 01-01-2006 | 01-01-2021 | |
| MARINUS PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 22-03-2021 | - |
| Independent Dir/Board Member | 22-03-2021 | - | |
| Hospitality Homes | Voorzitter | 01-01-2021 | - |
| Biomedical Sciences Careers Program, Inc. | Directeur/Bestuurslid | - | - |
Loopbaan van Sara Nochur
Eerdere bekende functies van Sara Nochur
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| DECIBEL THERAPEUTICS, INC. | Directeur/Bestuurslid | 06-12-2021 | 22-09-2023 |
| Independent Dir/Board Member | 06-12-2021 | 22-09-2023 | |
| THE MEDICINES COMPANY | Algemeen Adviseur | - | - |
| Biotrack, Inc. | Operationeel Directeur | - | - |
| Algemeen Adviseur | - | - | |
| DynaGen, Inc. | Corporate Officer/Principal | - | - |
Ischemix, Inc.
 Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Algemeen Adviseur | - | - |
Opleiding van Sara Nochur
| Massachusetts Institute of Technology | Doctorate Degree |
| University of Mumbai | Graduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 11 |
| India | 2 |
Operationeel
| General Counsel | 4 |
| Director/Board Member | 3 |
| Corporate Officer/Principal | 2 |
Sectoraal
| Health Technology | 7 |
| Finance | 2 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| MARINUS PHARMACEUTICALS, INC. | Health Technology |
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| DECIBEL THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
| DynaGen, Inc. | Health Technology |
| Biomedical Sciences Careers Program, Inc. | |
| Biotrack, Inc. | |
Ischemix, Inc.
Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Health Technology |
| Hospitality Homes |
- Beurs
- Insiders
- Sara Nochur
- Ervaring